نتائج البحث

المصدر: Illouz, F, Wang, D Y, Ye, F, Zhao, S, Johnson, D B, Gupta, A, De Felice, K M, Loftus, E V, Khanna, S, Beck, K E, Blansfield, J A, Tran, K Q, Feldman, A L, Hughes, M S, Royal, R E, Kammula, U S, Topalian, S L, Sherry, R M, Kleiner, D, Quezado, M, Lowy, I, Yellin, M, Rosenberg, S A, Yang, J C, Michot, J M, Bigenwald, C, Champiat, S, Collins, M, Carbonnel, F, Postel-Vinay, S, Berdelou, A, Varga, A, Bahleda, R, Hollebecque, A, Massard, C, Fuerea, A, Ribrag, V, Gazzah, A, Armand, J P, Amellal, N, Angevin, E, Noel, N, Boutros, C, Mateus, C, Robert, C, Soria, J C, Marabelle, A, Lambotte, O, Gonzalez, R S, Salaria, S N, Bohannon, C D, Huber, A R, Feely, M M, Shi, C, Marthey, L, Mateus, C, Mussini, C, Nachury, M, Nancey, S, Grange, F, Zallot, C, Peyrin-Biroulet, L, Rahier, J F, de Beauregard, M B, Mortier, L, Coutzac, C, Soularue, E, Lanoy, E, Kapel, N, Planchard, D, Chaput, N, Robert, C, Carbonnel, F, Benson, A B, Ajani, J A, Catalano, R B, Engelking, C, Kornblau, S M, Martenson, J A, McCallum, R, Mitchell, E P, O'Dorisio, T M, Vokes, E E, Wadler, S, Haanen, J B A G, Carbonnel, F, Robert, C, Kerr, K M, Peters, S, Larkin, J, Jordan, K, Bergqvist, V, Hertervig, E, Gedeon, P, Kopljar, M, Griph, H, Kinhult, S, Carneiro, A, Marsal, J, Hsieh, A H C, Ferman, M, Brown, M P, Andrews, J M, Trainer, H, Hulse, P, Higham, C E, Trainer, P, Lorigan, P, Hughes, J, Vudattu, N, Sznol, M, Gettinger, S, Kluger, H, Lupsa, B & Herold, K C 2006, ' Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 ', Journal of Clinical Oncology, pp. 2283-2289 . https://doi.org/10.1200/JCO.2005.04.5716Test

مصطلحات موضوعية: Male, Skin Neoplasms, Cytotoxic, medicine.medical_treatment, Autoimmunity, Dermatitis, Lymphocyte Activation, Gastroenterology, Immune-related adverse events, T-Lymphocyte Subsets, Adrenal Cortex Hormones, 80 and over, Immune-checkpoint inhibitor induced enterocolitis, Neoplasm Metastasis, Melanoma, Enterocolitis, Membrane Glycoproteins, Subcutaneous, Vaccination, Antibodies, Monoclonal, programmed cell death protein 1, Kidney Neoplasms, Neoplasm Proteins, Oncology, Disease Progression, chemically induced, Lung cancer, Nivolumab, gastroenteritis, Type 1, medicine.medical_specialty, Antineoplastic Agents, chemistry, Antigen, Antigens, CD, HLA-A2 Antigen, Diabetes Mellitus, Humans, Tumour neoantigen, Aged, ResearchInstitutes_Networks_Beacons/mcrc, Immunotherapy, medicine.disease, Peptide Fragments, Immunology, adverse effects, gastrointestinal tract, Peptides, Immune checkpoint blockade, Autoimmune, Cancer Research, colitis, T-Lymphocytes, Programmed Cell Death 1 Receptor, administration & dosage, Anti-CTLA-4, Hepatitis, immunology, Neoplasms, Monoclonal, CTLA-4 Antigen, Manchester Cancer Research Centre, Anti-PD-1 antibody, Cytotoxic T-lymphocyte-associated antigen 4, Middle Aged, CD, Differentiation, Female, immunotherapy, medicine.symptom, Intravenous, gp100 Melanoma Antigen, medicine.drug, Adult, etiology, Vitiligo, chemical and pharmacologic phenomena, Ipilimumab, Cancer Vaccines, Antibodies, Autoimmune Diseases, Injections, Gastrointestinal Agents, blood, Internal medicine, Immune Tolerance, medicine, Antigens, Vedolizumab treatment against irAEs, Carcinoma, Renal Cell, Salvage Therapy, therapy, business.industry, Cancer, Antigens, Differentiation, Infliximab, therapeutic use, physiology, Neoplasm, pathology, business